<?xml version="1.0" encoding="UTF-8"?>
<p>PC relapse risk is associated with clinical features such as tumor stage, Gleason score (GS)-based WHO PC grading system, and margin status [
 <xref rid="B36-genes-12-00257" ref-type="bibr">36</xref>,
 <xref rid="B58-genes-12-00257" ref-type="bibr">58</xref>]. As expected, these clinical features are risk factor of PC relapse (
 <xref rid="genes-12-00257-t002" ref-type="table">Table 2</xref>, see univariate Cox analysis). The LE gene panel score remains a predictor of PC recurrence after adjusting for age at diagnosis, tumor state, WHO PC grades, and margin status (
 <xref rid="genes-12-00257-t002" ref-type="table">Table 2</xref>). Among the 10 LE genes, ARFGEF2 remains predictive to PC recurrence after adjusting for these clinical factors at HR 0.9996, 95% CI 0.99925â€“0.9999, and 
 <italic>p</italic> = 0.0219; this is interesting considering its single gene status.
</p>
